You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Verzenio ® (abemaciclib) tablets
50mg, 100mg, 150mg, 200mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How does the mechanism of action of VERZENIO® (abemaciclib) differ from other CDK4/6 inhibitors?
Verzenio (abemaciclib) has not been studied in head-to-head clinical trials with other cyclin D-dependent kinases 4 and 6 inhibitors.
How does the mechanism of action of VERZENIO® (abemaciclib) differ from other CDK4/6 inhibitors?
Mechanism of Action of Abemaciclib as compared to other CDK 4 and 6 Inhibitors
Abemaciclib has not been studied in head-to-head clinical trials with other cyclin D-dependent kinases (CDK) 4 and 6 inhibitors.
The mechanism of action of abemaciclib is provided below.
Abemaciclib is an inhibitor of CDK4 and CDK6 and was most active against cyclin D1/CDK4 in enzymatic assays. In breast cancer, cyclin D1/CDK4 has been shown to promote phosphorylation of the retinoblastoma protein (Rb), cell proliferation, and tumor growth. Abemaciclib prevents Rb phosphorylation, blocking progression from G1 into S phase of the cell cycle, leading to suppression of tumor growth in preclinical models following short duration target inhibition. In estrogen receptor–positive breast cancer cell lines, sustained target inhibition by abemaciclib prevents rebound of Rb phosphorylation and cell cycle reentry, resulting in senescence and apoptosis. In breast cancer xenograft models, abemaciclib dosed daily without interruption at clinically relevant concentrations—as a single agent or in combination with antiestrogens—resulted in reduction of tumor size.1
For information on other CDK 4 and 6 inhibitors in this class, please contact the individual manufacturers of these drugs.
Enclosed Prescribing Information
Reference
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: September 16, 2025